Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of A-1 Cool Cream Efficacy for Treatment Atopic Dermatitis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT01174511
First received: August 2, 2010
Last updated: July 3, 2011
Last verified: July 2010

August 2, 2010
July 3, 2011
July 2011
November 2012   (final data collection date for primary outcome measure)
Evaluation of A-1 cool treatment by TIS score [ Time Frame: 5 DAYS ] [ Designated as safety issue: No ]
Initially, we will evaluate the disease severity in all the research subjects by SCORAD SCORE and TIS score.Thereafter we will apply to each subject's flexor aspects of the upper or lower limbs on one side the research product and on the other the placebo.This treatment will be given twice a day at specific times for 5 days. As ameasure to evaluate the efficacy of A-1 COOL treatment wiil be use the Three- item severity score (TIS)- reviewer redness, edema ,scratch marks.Severity of these symptoms wiil be evaluated from 0 to 3 points scale.
Same as current
Complete list of historical versions of study NCT01174511 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of A-1 Cool Cream Efficacy for Treatment Atopic Dermatitis
Clinical Trial Study for Evaluation of A-1 Cool Cream Efficacy for Treatment Patients With Atopic Dermatitis

Atopic dermatitis (AD) is a chronic inflammatory skin disease, affecting 20% of all babies and children around the world. Diagnosis of atopic dermatitis is clinical and depends on the existence of at least two out of the four following criteria: itching, a chronic disease course with exacerbations and remission ,rash with characteristic distribution and shape , atopia of the patient or family by history.

Initial treatment is based on keeping skin moist and avoiding a flare-provoking stimuli and allergens. The research product A-1 COOL is a skin cream approved by the Israeli Ministry of Health for cooling down of skin irritation. A-1 COOL is rich in herbal medicine ingredients and does not contain steroids.A-1 COOL can be beneficial in Atopic Dermatitis patients due to its following action mechanisms: sealing of the inflamed skin and retention of water, prevention of the itching cycle by keeping the skin moist, disinfection of the skin by the herbal ingredients.

Atopic dermatitis (AD) is a chronic inflammatory skin disease, affecting 20% of all babies and children around the world. In 90% of the cases the disease first appears before the age of five and in 65% of the cases it is already apparent at infancy but it may occur at any age.

Diagnosis of atopic dermatitis is clinical and depends on the existence of at least two out of the four following criteria: itching, a chronic disease course with exacerbations and remission ,rash with characteristic distribution and shape , atopia of the patient or family by history.

Initial treatment is based on keeping skin moist and avoiding a flare-provoking stimuli and allergens. Topical ointments which grease the skin have shown and reduction of skin inflammation. These products can include active substances such as steroids and anti-inflammatory compounds.

Systemic treatments for atopic dermatitis mainly include steroids and cyclosporine.

The research product A-1 COOL is a skin cream approved by the Israeli Ministry of Health for cooling down of skin irritation. A-1 COOL is rich in herbal medicine ingredients and does not contain steroids.A-1 COOL can be beneficial in Atopic Dermatitis patients due to its following action mechanisms: sealing of the inflamed skin and retention of water, prevention of the itching cycle by keeping the skin moist, disinfection of the skin by the herbal ingredients.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Supportive Care
ATOPIC DERMATITIS
Drug: A -1 Cool Cream,Vaselin ointment
A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
  • Experimental: A-1 COOL cream

    A research product - A-1 COOL cream contain herbal medicine plants basically :

    1. WATER PETROLATUM
    2. WILD YAM (DIOSCOREA VILLOSA) EXTRACT
    3. SORBITAN SESQUIOLEATE
    4. CALENDULA OFFICINALIS EXTRACT
    5. MINERAL OIL
    6. ARNICA MONTANA EXTRACT
    7. MICROCRYSTALLINE WAX
    8. LICORICE (GLYCYRRHIZA GLABRA) EXTRACT
    9. DECYL OLEATE
    10. DICOCOYL PENTAERYTHRITYL DISTEARYL CITRATE
    11. BEESWAX
    12. ALUMINUM STEARATES
    Intervention: Drug: A -1 Cool Cream,Vaselin ointment
  • Placebo Comparator: Vaselin ointment
    Using the study as placebo.
    Intervention: Drug: A -1 Cool Cream,Vaselin ointment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
30
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • patient with atopic dermatitis,
  • Hebrew-speaking men and women,
  • over 18 years old.

Exclusion Criteria:

  • hospital where the diagnosis of atopic dermatitis is not sure,
  • patients under the age of 18, pregnant women, no - helpless, soldiers and prisoners,
  • patients with atopic dermatitis treated with systemic preparations such as cyclosporine, steroids, antibiotics, methotrexate, biological preparations.
Both
18 Years and older
No
Contact: LEMSTER NATALYA, MD 97226776114 LEMSTER20@YAHOO.COM
Contact: INGBER ARIEH, PROF. 97226776114 aingber@live.com
Not Provided
 
NCT01174511
0124-10-HMO-ctil
Yes
Prof. Arieh Ingber - Head of Department of Dermatology and Venereology - Hadassah Medical Center, Hadassah Medical Organization, Jerusalem, Israel
Hadassah Medical Organization
Not Provided
Not Provided
Hadassah Medical Organization
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP